10th of May

New Publication: Our team uncovers molecular biomarkers of tumour response to neoadjuvant endocrine therapy in ER+/HER2- Breast Cancer

Our Breast Cancer Research Group at Biogipuzkoa has recently published a study in Translational Oncology entitled:
“Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response.”
DOI: 10.1016/j.tranon.2025.102407

In this multicentre study, we analysed tumour samples from patients with ER+/HER2- breast cancer treated with neoadjuvant endocrine therapy (NET), using the PAM50 gene expression panel and immunohistochemistry. Our findings show that changes in tumour subtype—from luminal A to normal-like—as well as decreases in ROR score and p53 expression, are associated with better response to NET.

This work was led by Joanna I. López-Velazco, Ander Urruticoechea, María M. Caffarel, Sara Manzano, and collaborators from various institutions. The results highlight promising biomarkers that could help personalise treatment and support wider use of NET in clinical practice.

Read the full notice from our institute here: